免疫检查点抑制剂诱导的甲状腺功能障碍与较高体重指数相关
该单中心回顾性分析纳入2014年1月至2018年12月接受抗PD-1/L1治疗的185例癌症患者,基线甲状腺功能正常且有BMI数据。结果显示,发生显性甲状腺功能障碍者平均BMI高于甲状腺功能正常者(27.3±6.0 vs 24.9±4.5,P=.03),显性甲状腺毒症与较高BMI相关(28.9±5.9 vs 24.9±4.5,P<.01),且肥胖组显性甲状腺毒症发生更早。
要点
- 185例抗PD-1/L1治疗患者中,72例(38.9%)发生任何甲状腺功能障碍,41例(22.1%)发生显性甲状腺功能障碍。
- 显性甲状腺功能障碍组平均BMI高于甲状腺功能正常组(27.3±6.0 vs 24.9±4.5,P=.03)。
- 显性甲状腺毒症组BMI高于甲状腺功能正常组(28.9±5.9 vs 24.9±4.5,P<.01),显性甲状腺功能减退组与甲状腺功能正常组无显著差异(26.7±5.5 vs 24.9±4.5,P=.10)。
核心结论
- 接受PD-1/L1抑制剂治疗的患者,随着BMI升高,更可能发生甲状腺免疫相关不良事件,尤其是显性甲状腺毒症。
- 显性甲状腺毒症在肥胖患者中比在较瘦患者中发生更早。
研究设计与样本
- 单中心、回顾性分析,纳入2014年1月至2018年12月接受抗PD-1/L1治疗的185例癌症患者,基线甲状腺功能正常且有可用BMI数据。
主要发现
- 72例(38.9%)发生任何甲状腺功能障碍,41例(22.1%)发生显性甲状腺功能障碍。
- 显性甲状腺功能障碍组平均BMI高于甲状腺功能正常组(27.3±6.0 vs 24.9±4.5,P=.03)。
- 显性甲状腺毒症组BMI高于甲状腺功能正常组(28.9±5.9 vs 24.9±4.5,P<.01)。
- 显性甲状腺功能减退组与甲状腺功能正常组BMI无显著差异(26.7±5.5 vs 24.9±4.5,P=.10)。
- 显性甲状腺毒症发生时间:低-正常BMI组57.5天(IQR 31.8-78.8),超重组38.0天(IQR 26.8-40.5),肥胖组23.0天(IQR 21.0-28.0),P=.02。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Obesity is a proinflammatory metabolic state that may play a role in the development of immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy. OBJECTIVE: To characterize the association between body mass index (BMI) and thyroid irAEs. METHODS: We performed a single-center, retrospective analysis of 185 cancer patients treated with anti-PD-1/L1 from January 2014 to December 2018. Patients with normal thyroid function at baseline and available BMI were included. MAIN OUTCOME MEASURES: The primary endpoint was difference in BMI in patients who developed overt thyroid dysfunction versus those who remained euthyroid following anti-PD-1/L1 initiation. Additional endpoints included any (overt or subclinical) thyroid dysfunction, overt thyrotoxicosis or overt hypothyroidism, and time to development of dysfunction according to BMI. RESULTS: Any thyroid dysfunction developed in 72 (38.9%) patients and 41 (22.1%) developed overt thyroid dysfunction. Mean BMI was higher in those with overt thyroid dysfunction versus euthyroid (27.3 ± 6.0 vs 24.9 ± 4.5, P = .03). Development of overt thyrotoxicosis versus remaining euthyroid was associated with higher BMI (28.9 ± 5.9 vs 24.9 ± 4.5; P < .01), whereas overt hypothyroidism was not (26.7 ± 5.5 vs 24.9 ± 4.5, P = .10). Overt thyrotoxicosis developed within 57.5 (interquartile range [IQR] 31.8-78.8) days of treatment in the low-normal BMI group, 38.0 (IQR 26.8-40.5) days in the overweight group, and 23.0 (IQR 21.0-28.0) days in the obese group (P = .02). CONCLUSIONS: Patients treated with PD-1/L1 inhibitors were more likely to develop thyroid irAEs, specifically overt thyrotoxicosis, with increasing BMI. Overt thyrotoxicosis occurred earlier in obese versus leaner patients. These data highlight the complex interplay between obesity and immune response in immune checkpoint inhibitor-treated patients.
引用
- Pollack R, Ashash A, Cahn A, et al. Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index. J Clin Endocrinol Metab. 2020. PMID: 32668461. doi:10.1210/clinem/dgaa458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。